Abraham Heifets

Abraham Heifets, Co-founder and CEO of Atomwise, modifies the landscape of drug discovery using AI. He dives into the use of deep learning for predicting molecule binding, tackling diseases once deemed 'undruggable.' Heifets discusses the synergy of AI with traditional methods, highlighting breakthroughs in protein structure understanding. He also emphasizes the importance of innovative collaborations in AI-driven drug development, showcasing how these advances could revolutionize treatments for diseases like cancer and Alzheimer's.